Table 2.
Primary treatment by tumor histology
| Treatment, n (%) | AC | SCC | p |
|---|---|---|---|
| Surgery | 10 (28) | 23 (16) | 0.169 |
| Surgery + adjuvant chemoradiationab | 12 (33) | 36 (25) | 0.437 |
| Neo-adjuvant chemoradiationa with intent for surgeryc | 14 (39) | 70 (49) | 0.371 |
| Definitive chemoradiationad | 0 (0) | 12 (8) | 0.154 |
| Brachytherapy alonee | 0 (0) | 1 (1) | 1 |
| Neo-adjuvant chemotherapy + conizationf | 0 (0) | 1 (1) | 1 |
AC adenocarcinoma (n = 36), SCC Squamous Cell Carcinoma (n = 143); a If possible, chemotherapy (C) was administered concomitantly and consisted of weekly single-agent cisplatin at 40 mg/m2; b In 11/33 AC/SCC patients this includes a brachytherapeutic boost; c 7 SCC patients did not receive surgery and 1/3 AC/SCC patients received a brachytherapeutic boost due to positive or doubtful margins; e due to co-morbidities; f fertility sparing